Carbon Reduction Policy

Oranda Therapeutics Limited (“Oranda”) is a rare-disease pharmaceutical company focused on improving patient access to affordable rare-disease medicines. The UK entity operates as an affiliate of Oranda’s Irish parent company and has been established to support future UK market activity, including NHS procurement.

Whilst the UK entity was incorporated in January 2024, operational activity remained limited during the company’s development phase as the wider business secured investment, established its organisational structure and prepared for commercial launch. Accordingly, 2026 has been selected as the first meaningful operational baseline year for carbon reporting purposes.

As a newly established UK affiliate with limited direct operational activity, a predominantly remote-working model, and no directly controlled UK premises, vehicles, or manufacturing facilities, this inaugural Carbon Reduction Plan has been prepared using a proportionate approach. Where actual activity data is not yet available, reasonable assumptions have been applied and clearly documented.

The purpose of this Carbon Reduction Plan is to support NHS procurement requirements, demonstrate Oranda’s commitment to achieving Net Zero greenhouse gas emissions by 2050, and establish a practical framework for measuring, managing and reducing emissions as the organisation grows. As operational activity increases and data collection processes mature, future Carbon Reduction Plans will be based on annual reporting using actual organisational data. This report covers UK operations only.

Emissions

Baseline emissions

Baseline emissions are a record of greenhouse gases produced prior to the introduction of any strategies to reduce emissions. They are the reference point against which emissions reduction can be measured. Reported in line with PPN 06/21.

6.85 tCO₂e Total baseline emissions, 2026

Baseline emissions for 2026 by scope, category and source, in tonnes of carbon dioxide equivalent.
Emissions scope	Category	Source	tCO₂e (2026)
Scope 1	Direct fuel combustion, company vehicles, fugitive emissions	Direct. None identified	0
Scope 2 (location-based)	Purchased electricity, heating and cooling	Indirect. No direct electricity contracts identified	0
Scope 3	Relevant value chain emissions	Indirect	6.85
Total emissions (location / market-based)			6.85

Scope 3 assessment

As a newly established organisation with a predominantly remote workforce and limited direct operational activity, Oranda Therapeutics has undertaken a proportionate assessment of Scope 3 emissions sources relevant to its current operating model. This baseline focuses on the most material emission sources currently identifiable and establishes a framework for improved data collection and reporting as the business grows.

Pharmaceutical manufacturing, quality release, warehousing and distribution activities have been recognised as potentially significant future Scope 3 emission sources. These activities have not been quantified within this initial baseline due to the current absence of supplier-specific emissions data, but they have been identified as future reporting priorities.

Scope 3 emissions for 2026 by category, in tonnes of carbon dioxide equivalent.
Scope 3 category	tCO₂e (2026)
1. Purchased goods and services	Qualitative assessment only
2. Capital goods	Not material
3. Fuel-related emissions	Not material
4. Upstream transportation and distribution	Future reporting priority
5. Waste generated in operations	Not material
6. Business travel	5.8
7. Employee commuting	0.15 (estimated, remote-first model)
8. Homeworking	0.9
9. Upstream leased assets	Not material
10. Downstream transportation and distribution	Future reporting priority
11. End-of-life treatment of sold products	Future reporting priority

Net Zero

Targets and commitments

Our commitment

Oranda Therapeutics Limited is committed to achieving Net Zero greenhouse gas emissions across its operations and value chain by 2050, in line with UK Government and NHS Net Zero ambitions.

2027

Establish robust carbon reporting

Establish annual carbon reporting and emissions data collection processes.

2028

Embed sustainability into procurement

Integrate ESG considerations into supplier engagement and procurement activities.

2030

Improve supply chain emissions transparency

Improve management of emissions associated with pharmaceutical manufacturing and supply chains.

Targets will be reviewed periodically as Oranda's operations, supply chain and emissions data maturity develop.

In place today

Completed and current carbon reduction measures

Remote-first operating model

Oranda operates with a predominantly remote workforce and limited physical infrastructure, reducing emissions associated with office occupancy, commuting and facilities management.
Lean organisational structure

As an early-stage pharmaceutical company, Oranda maintains a lean organisational structure and outsources specialist functions where appropriate, minimising direct operational emissions.
Digital collaboration

Meetings, document management and project collaboration are undertaken primarily through digital platforms, reducing the need for travel and paper-based processes.

Ahead

Planned carbon reduction projects

2027

Establish emissions data collection processes

Record business travel expenditure and mileage
Capture coworking space usage
Review homeworking assumptions annually
Produce, annually review and publish Oranda's greenhouse gas inventory

2028

Sustainable procurement and supplier engagement

Integrate environmental and ESG considerations into supplier selection, review and due diligence processes
Request relevant environmental, quality, labour standards and governance information from key manufacturing, release, warehousing and logistics partners
Engage key supply chain partners to improve visibility of supplier ESG and environmental performance

2030

Supply chain emissions management

Improve visibility of emissions associated with pharmaceutical manufacturing
Improve understanding of pharmaceutical distribution and logistics emissions
Assess opportunities to reduce emissions across the value chain

Declaration and sign off

This Carbon Reduction Plan has been prepared in accordance with PPN 06/21 and current Carbon Reduction Plan guidance, as applicable to NHS procurement requirements.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard, and use the appropriate Government emission conversion factors for greenhouse gas company reporting.

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body) and came into effect on 14th July 2026.

Signed on behalf of Oranda Therapeutics Limited: John Irwin
Role: Co-Founder

Reporting methodology

Greenhouse gas emissions have been calculated in accordance with the UK Government Environmental Reporting Guidelines and the Greenhouse Gas (GHG) Protocol Corporate Accounting and Reporting Standard. Emissions factors have been sourced from the UK Government Greenhouse Gas Reporting Conversion Factors for Company Reporting (2026 edition or latest available at the time of reporting).

As a newly established organisation operating with a small, predominantly remote workforce and limited operational activity, Oranda Therapeutics has adopted a proportionate approach to emissions reporting. Where actual activity data was not available, reasonable assumptions and estimation methodologies have been applied based on the organisation’s operating model, workforce profile and known business activities.

The organisational boundary has been established using an operational control approach. Scope 1, Scope 2 and relevant Scope 3 emission sources have been assessed in line with the GHG Protocol. Due to the absence of owned vehicles, combustion equipment or dedicated office facilities, no Scope 1 or Scope 2 emissions were identified within the reporting boundary.

Relevant Scope 3 emission categories were identified with reference to the GHG Protocol Corporate Value Chain (Scope 3) Standard. Emissions associated with employee homeworking, employee commuting, business travel and shared workspace occupancy were assessed using activity-based estimates and government conversion factors where appropriate. Scope 3 categories not currently considered material to Oranda’s operations have been qualitatively assessed and will be reviewed annually as the business grows.

Given Oranda’s early stage of operational development, limited direct UK activity and the absence of a full year of measured activity data, this initial Carbon Reduction Plan uses calendar year 2026 as the first meaningful operational baseline. The reporting boundary covers UK operations only. Wider European and group-level reporting boundaries will be considered as Oranda’s operations mature.

This Carbon Reduction Plan establishes Oranda’s initial emissions baseline and provides a framework for improving data quality and reporting coverage over time. As operational activity develops, future inventories will transition from estimated data towards actual measured activity data wherever practicable.

Key assumptions

As Oranda Therapeutics is a newly established organisation and has not yet completed a full reporting year, certain greenhouse gas emissions have been estimated using reasonable assumptions based on the organisation's current operating model. The following assumptions have been applied:

Key assumptions behind the carbon footprint calculation, by area.
Area	Assumption
Workforce	UK-related activity currently comprises a small remote-working team, including UK-based leadership and employee activity and contractor support. The UK affiliate currently has limited direct operational activity, with wider employees and contractors engaged through the Irish parent company.
Working model	Predominantly remote. Homeworking emissions have been estimated using a 1.5 full-time equivalent assumption to reflect UK-related activity undertaken by UK-based personnel and contractor support during the 2026 initial reporting period.
Coworking	Occasional use.
Vehicles	No company vehicles.
Offices	No UK dedicated leased office.
Commuting	Employee commuting emissions have been estimated using a conservative assumption of limited commuting activity associated with Oranda's predominantly remote operating model. Homeworking emissions have been estimated using recognised UK homeworking emission factors and reflect the company's current remote-first approach.
Business travel	Estimated at 5.8 tCO2e for the 2026 initial reporting period. This estimate is based on anticipated UK-related business travel by the UK-based director, including quarterly travel to Ireland for board meetings, European business travel and one annual long-haul conference.
UK assets	Oranda does not directly own or lease UK office, warehouse, laboratory, manufacturing or distribution assets. UK product storage, if required, is expected to be managed by third-party logistics partners.
Supply chain, manufacturing and logistics	Emissions associated with third-party manufacturing, quality release, warehousing and distribution have been assessed qualitatively in this initial baseline and identified as future Scope 3 reporting priorities, pending availability of supplier-specific emissions data.